ライフサイエンスコーパス: intensive chemotherapy

1 d (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).

2 yeloid leukaemia who were not candidates for intensive chemotherapy.

3 patients who are unlikely to survive despite intensive chemotherapy.

4 them were treated with brief (<4 months) but intensive chemotherapy.

5 ter mobilization with either intermediate or intensive chemotherapy.

6 et transfusions in patients who undergo dose-intensive chemotherapy.

7 ndrome, were nonrandomly assigned to receive intensive chemotherapy.

8 ute myeloid leukemia who were ineligible for intensive chemotherapy.

9 ce host toxicity in patients undergoing dose intensive chemotherapy.

10 CL patients, particularly those treated with intensive chemotherapy.

11 40% of these patients relapse after standard intensive chemotherapy.

12 oid leukemia (AML) is still dismal even with intensive chemotherapy.

13 ts Of 2,992 patients, 1,588 (53.1%) received intensive chemotherapy.

14 y diagnosed with non-M3 AML and were fit for intensive chemotherapy.

15 yeloid leukemia (AML) not considered fit for intensive chemotherapy.

16 ermediate-risk cytogenetics AML treated with intensive chemotherapy.

17 ents with malignant hemopathies treated with intensive chemotherapy.

18 py and to unfit patients, unable to tolerate intensive chemotherapy.

19 ologic features and a poor prognosis despite intensive chemotherapy.

20 We aimed to improve these results using more intensive chemotherapy.

21 tients develop disease that is refractory to intensive chemotherapy.

22 ients older than 60 years who do not receive intensive chemotherapy.

23 patients in terms of quality of life versus intensive chemotherapy.

24 r= 65 years of age and deemed unsuitable for intensive chemotherapy.

25 ) who were not candidates for or who refused intensive chemotherapy.

26 irradiation, and ABMT versus three cycles of intensive chemotherapy.

27 ntensity therapy in older patients unfit for intensive chemotherapy.

28 onfers a poor prognosis with use of standard intensive chemotherapy.

29 four cycles of cyclophosphamide-based, dose-intensive chemotherapy.

30 randomly assigned to receive six courses of intensive chemotherapy (117 patients) or autologous tran

31 Despite intensive chemotherapy, 20% of pediatric patients and ov

32 otherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherap

33 is: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherap

34 ia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older

35 %) >/= 70 years of age with AML is poor with intensive chemotherapy (8-week mortality >/= 30%; median

36 Many patients receiving dose-intensive chemotherapy acquire thrombocytopenia and need

37 s in a lower risk of disease recurrence than intensive chemotherapy alone, overall outcome following

38 blastoma cells or to receive three cycles of intensive chemotherapy alone.

39 lysis focused on adult patients who received intensive chemotherapy and a mold-active AFP for at leas

40 rrent AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem

41 Consolidation was with intensive chemotherapy and autologous bone marrow transp

42 th metastatic neuroblastoma (NB) die despite intensive chemotherapy and bone marrow transplantation.

43 n of long-term complications associated with intensive chemotherapy and cranial irradiation.

44 ) and large-cell lymphoma (LCL) treated with intensive chemotherapy and hematopoietic colony-stimulat

45 increase in the number of children receiving intensive chemotherapy and marrow transplantation, but a

46 uration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic

47 Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effectiv

48 cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1)

49 Intensive chemotherapy and stem cell transplantation in

50 ent lymphoma ranges from watchful waiting to intensive chemotherapy and stem cell transplantation.

51 Despite intensive chemotherapy and surgical resection, approxima

52 marrow can protect mice from time- and dose-intensive chemotherapy and that the combination of 6-BG

53 ents to other investigational therapies (eg, intensive chemotherapy and/or autologous stem-cell trans

54 p (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556

55 rapy, treatment of patients not eligible for intensive chemotherapy, and novel agents for relapsed/re

56 chemotherapy; another 22 underwent surgery, intensive chemotherapy, and radiation therapy.

57 n be administered safely in combination with intensive chemotherapy, and the degree of Bcl-2 downmodu

58 et transfusions in patients who undergo dose-intensive chemotherapy, and thus may permit chemotherapy

59 ia (AML) who are not considered suitable for intensive chemotherapy are limited.

60 ovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support a

61 ients with AML age >/= 55 years treated with intensive chemotherapy as part of Southwest Oncology Gro

62 This is the first study to show that intensive chemotherapy, as given in the A-BFM regimen, c

63 HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic

64 have multiple benefits in patients receiving intensive chemotherapy at high risk for infection.

65 mparing 3 intensive postremission therapies: intensive chemotherapy, autologous transplantation (ABMT

66 Survival after failure of intensive chemotherapy, azacitidine, or decitabine was m

67 /= 20% blasts) treated with cytarabine-based intensive chemotherapy between 1990 and 2008 to identify

68 After three courses of intensive chemotherapy, bone marrow was harvested from p

69 randomized study comparing standard vs less-intensive chemotherapy, both combined with imatinib, for

70 be successfully treated into remission with intensive chemotherapy, but it routinely relapses.

71 ortens the time to neutrophil recovery after intensive chemotherapy, but its role in the treatment of

72 urkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy

73 We conclude that epigenetic priming of intensive chemotherapy can be safely delivered in an att

74 apy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcom

75 After intensive chemotherapy, CD8+ T cells had a faster effect

76 prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antib

77 In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission impr

78 After intensive chemotherapy, FL levels rose to a mean of 488

79 characterize early lymphocyte recovery after intensive chemotherapy for acute myelogenous leukemia (A

80 Adults who received intensive chemotherapy for ALL benefited from G-CSF trea

81 The addition of more intensive chemotherapy for anaplastic histology disease,

82 o-treat analysis: 36 +/- 5.8 percent for the intensive-chemotherapy group as compared with 38 +/- 6.4

83 urvival at three years for the nonrandomized intensive-chemotherapy group was 39 +/- 5.1 percent, and

84 with autologous transplantation than in the intensive-chemotherapy group.

85 ylating agents (azacitidine and decitabine), intensive chemotherapy (ICT), and allogeneic stem-cell t

86 For patients who had not received prior intensive chemotherapy (ie, with secondary AML or high-r

87 Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with

88 B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 ant

89 is associated with similar survival rates as intensive chemotherapy in older patients with newly diag

90 trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellu

91 Rapid recovery of CD4+ T cells after intensive chemotherapy is limited by an age-dependent de

92 After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoi

93 t our institution between 2000 and 2010 with intensive chemotherapy (n = 557) or azacitidine- or deci

94 Other patients may receive intensive chemotherapy or autologous transplantation; we

95 emia who achieved long-term remissions after intensive chemotherapy or bone marrow transplantation (B

96 ch represents a shift from the paradigm that intensive chemotherapy or radiotherapy, or both, is need

97 fractory mantle cell lymphoma ineligible for intensive chemotherapy or stem-cell transplantation have

98 e-threatening hematologic disorders received intensive chemotherapy or total-body irradiation and the

99 Despite intensive chemotherapy plus trastuzumab for patients wit

100 went a significant change in 1988 when a new intensive chemotherapy program was introduced (CALGB 881

101 er autologous bone marrow transplantation or intensive chemotherapy prolongs event-free survival equa

102 We aimed to assess whether an intensive chemotherapy protocol that had a 10-day interv

103 In conclusion, combining lestaurtinib with intensive chemotherapy proved feasible in younger patien

104 o middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadel

105 nal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated

106 ly reported a high response rate with a dose-intensive chemotherapy regimen in 24 children with high-

107 coma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisp

108 ll achieve durable remission with this brief intensive chemotherapy regimen.

109 be treated as cytogenetic high risk, receive intensive chemotherapy (regimen C), and will only be rec

110 ildren with HR-ALL were randomly assigned to intensive chemotherapy regimens (New York I [NY I] or NY

111 Intensive chemotherapy regimens have led to a substantia

112 We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated

113 al was superior among those who had received intensive chemotherapy regimens instead of lower-dose re

114 Because intensive chemotherapy regimens used in most childhood c

115 The intensive chemotherapy regimens used to treat acute myel

116 , respectively) after the change to the more intensive chemotherapy regimens.

117 mia (ALL) now achieve remission with current intensive chemotherapy regimens.

118 ommended for patients receiving IFL or other intensive chemotherapy regimens.

119 Although intensive chemotherapy remains the mainstay of acute mye

120 in (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group).

121 ddition of autologous BMT to four courses of intensive chemotherapy substantially reduces the risk of

122 iagnosed in the first trimester necessitates intensive chemotherapy that is likely to induce fetal ma

123 ferative B-cell neoplasm and is treated with intensive chemotherapy that, because of its toxicity, is

124 cutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the

125 ly patients with AML who were unsuitable for intensive chemotherapy was manageable and typical of a c

126 0 years with newly diagnosed AML and planned intensive chemotherapy were enrolled at a single institu

127 s represents the most common complication of intensive chemotherapy, which has a severe adverse impac

128 proximately 10% of AML patients treated with intensive chemotherapy, which to a large extent can be p

129 gery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transpl

130 Dose-intensive chemotherapy with intravenous melphalan and gr

131 health and to maintain high cure rates, dose-intensive chemotherapy with limited cumulative doses was

132 val than that of older children treated with intensive chemotherapy with or without ABMT.

133 openia and to assist patients receiving dose-intensive chemotherapy with or without stem cell support

134 ropenia or to assist patients receiving dose-intensive chemotherapy with or without stem cell support

135 eat FN and to assist patients receiving dose-intensive chemotherapy with or without stem cell support

136 Most importantly, intensive chemotherapy with or without stem cell transpl

137 All patients were treated with intensive chemotherapy, with or without haemopoietic ste

138 nts with ALL can be cured with risk-adjusted intensive chemotherapy without stem-cell transplantation